Pacira Pharmaceuticals and Nuance Biotech Announce License Agreement for EXPAREL® in China Pharmaceutical Investing
Fortress Biotech Announces Publication of Phase 1 Data on CNDO-109-Activated Allogeneic Natural Killer Cells in Acute Myeloid Leukemia in Biology of Blood and Marrow Transplantation Biotech Investing
Xanthic Biopharma CEO: Our Business Model Provides Value-add Opportunities for Licensed Producers Cannabis Investing News
Aequus Announces First Canadian Cataract Procedures Using Zepto Capsulotomy System Pharmaceutical Investing
Genentech Announces New OCREVUS (Ocrelizumab) Data on Long-Term Disability Benefits Genetics Investing
FDA Approves Merck’s KEYTRUDA (pembrolizumab) for Treatment of Refractory or Relapsed Primary Mediastinal Large B-Cell Lymphoma Pharmaceutical Investing
ContraVir Pharmaceuticals Announces the Approval of the IND and Initiation of the Clinical Development Program of CRV431 in the United States Biotech Investing
Rhythm Pharmaceuticals Completes Pivotal Enrollment in Two Ongoing Phase 3 Clinical Trials Pharmaceutical Investing
Arsanis Out-Licenses Preclinical Stage Klebsiella pneumoniae Monoclonal Antibodies from ASN300 Program Biotech Investing
